Spike S1 (B.1.1.7; Alpha Variant) (SARS-CoV-2): ACE2 TR-FRET Assay Kit

Catalog #
78282
$930 *
Size: 384 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Spike S1 (B.1.1.7; Alpha Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 (B.1.1.7; Alpha Variant) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).

Synonyms
SARS-CoV-2 inhibition kit, ACE2 inhibition kit, SARS TR-FRET kit, ACE2 homogenous kit, B.1.1.7 Variant, Alpha Variant, alpha assay kit
Product Info
Storage and Usage
Citations
Assay Kit Format
TR-FRET
Species
SARS-CoV-2
Supplied As
Homogeneous 384 reaction format
Materials Required But Not Supplied

Fluorescence microplate reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET)
Adjustable micropipettor and sterile tips

Format
Catalog # Name Amount Storage
100705 ACE2, His-Tag, Eu-labeled* 2 x 2 µg -80°C
101002 Spike S1* (B.1.1.7 Variant), Avi-His-tag, Biotin Labeled (16-685) (SARS-CoV-2) 25 µg -80°C
  Dye-labeled acceptor 3 x 10 µl -20°C
79953 3x ACE2-Spike TR-FRET Buffer 4 ml -20°C
79969 384-well white microplate 1 Room Temp

*The initial concentration of both ACE2 and Spike S1 is lot-specific and will be indicated on the tube containing the protein.

Background

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection.

SARS-CoV-2 (B.1.1.7), also known as Alpha variant, was first identified in the United Kingdom in the summer of 2020. This variant contains mutations N501Y, A570D, D614G, P681H, and deletions 69-70HV and 144Y in the Spike protein that may lead to higher transmissibility and infectivity.

References

1. Hoffmann, M. et al. Cell, 181:1-10
2. Yan, R. et al. 2020. Science 367(6485):1444-1448